Warning: The NCBI web site requires JavaScript to function. more...
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels.
Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W.
Arthritis Res Ther. 2006;8(1):R6.
Related citations
B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, Shaham B, Phei WC, Garza J, Bernstein B, Stohl W.
Arthritis Rheum. 2009 Nov;60(11):3400-9.
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM.
Arthritis Rheum. 2003 Dec;48(12):3475-86.
Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.
Ann Rheum Dis. 2009 Jun;68(6):997-1002. Epub 2008 Aug 2.
B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT, Collins CE, Yang HT, Migone TS, Stohl W.
Ann Rheum Dis. 2008 Aug;67(8):1132-8. Epub 2007 Oct 29.
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W.
Arthritis Rheum. 2008 Aug;58(8):2453-9.
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
Ann Rheum Dis. 2008 Jul;67(7):1011-6. Epub 2007 Oct 25.
Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients.
Lin Z, Dan-Rong Y, Xiao-Qing T, Hao W, Hong-Lian G, Xian-Tao K, Ren-Qian Z, Jiyu L.
J Clin Lab Anal. 2007;21(3):183-7.
B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A, Nikolaisen C, Nossent HC.
Lupus. 2006;15(9):570-6.
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
Ritterhouse LL, Crowe SR, Niewold TB, Merrill JT, Roberts VC, Dedeke AB, Neas BR, Thompson LF, Guthridge JM, James JA.
Arthritis Rheum. 2011 Dec;63(12):3931-41. doi: 10.1002/art.30598.
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM.
Ann Rheum Dis. 2004 Sep;63(9):1096-103.
Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R.
Clin Biochem. 2006 Dec;39(12):1131-7. Epub 2006 Oct 5.
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Cheema GS, Roschke V, Hilbert DM, Stohl W.
Arthritis Rheum. 2001 Jun;44(6):1313-9.
Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B.
Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N.
J Immunol. 2008 Aug 1;181(3):2211-9.
Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.
Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K.
Genes Immun. 2002 Nov;3(7):424-9.
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).
Stohl W.
Arthritis Res Ther. 2010;12(2):111. Epub 2010 Apr 22.
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA.
Arthritis Res Ther. 2010;12(2):R48. Epub 2010 Mar 19.
B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients.
Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, Ferrara DE, Labat K, Sattler FR, Pierangeli SS, Hilbert DM.
Clin Immunol. 2002 Aug;104(2):115-22.
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
Arthritis Rheum. 2006 Mar;54(3):723-32.
Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein.
Curr Opin Rheumatol. 2002 Sep;14(5):522-8. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on